Lenox Hill Hospital

Running trials

• Recruiting

  Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  NCT07388524· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

  NCT07594119· Phase 3· Rapport Therapeutics Inc.· Source

• Recruiting

  Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory

  NCT07584681· Northwell Health· Source

• Recruiting

  Single Chamber Atrial Leadless Pacing for Isolated Sinus Node Dysfunction

  NCT07638995· Northwell Health· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

  NCT07523750· Biosense Webster, Inc.· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07185009· Phase 3· Sanofi· Source

• Enrolling by invitation

  SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study

  NCT07116668· SafeHeal Inc· Source

• Recruiting

  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  NCT06686771· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

  NCT06698458· Alpha Tau Medical LTD.· Source

• Recruiting

  High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  NCT06992427· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

  NCT06805305· Phase 2· Diakonos Oncology Corporation· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Non-Invasive Preeclampsia Screening and Biobank

  NCT06643741· Sequenom, Inc.· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

  NCT06498960· CereVasc Inc· Source

• Active, not recruiting

  A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

  NCT06455098· Biosense Webster, Inc.· Source

• Recruiting

  Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

  NCT06235697· Phase 3· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

  NCT05863351· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· Phase 3· NRG Oncology· Source

• Recruiting

  LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

  NCT06073431· University of Rochester· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

  NCT06052059· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Azeliragon in MGMT Unmethylated Glioblastoma

  NCT05986851· Phase 2· Cantex Pharmaceuticals· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

  NCT04485949· Phase 2· Imvax· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· NRG Oncology· Source

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Alleviant ALLAY-HF Study

  NCT05685303· Alleviant Medical, Inc.· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

  NCT04929041· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  XIENCE Skypoint Large Vessel Post Approval Study

  NCT05423379· Abbott Medical Devices· Source

• Recruiting

  Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers

  NCT05606133· Northwell Health· Source

• Recruiting

  A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

  NCT05303467· Phase 1· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

Showing 50 of 80.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer4 recruiting
• Lung cancer4 recruiting
• Prostate cancer3 recruiting
• Atrial fibrillation2 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Glioblastoma2 recruiting
• Head and neck cancer2 recruiting
• Kidney cancer2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Ulcerative colitis2 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  NCT06581328· Phase 4· Takeda· Source

• Completed

  A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

  NCT06159725· Phase 1/2· Clarametyx Biosciences, Inc.· Source

• Completed

  Reduce Loneliness in Care Partners of Persons With AD/ADRD

  NCT05460494· Northwell Health· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Completed

  Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

  NCT05570006· Phase 2· AbbVie· Source

• Completed

  A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

  NCT05443594· Boston Scientific Corporation· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Terminated

  SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

  NCT05010850· SafeHeal Inc· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

  NCT04809363· Phase 4· Takeda· Source

• Completed

  The Young Heart Study

  NCT04462159· Northwell Health· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

  NCT04075825· Phase 3· Takeda· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009· Phase 2/3· NRG Oncology· Source

• Completed

  Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

  NCT01675440· Medtronic Cardiovascular· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Cystic fibrosis15 works · 1 trial
• Meningioma8 works · 1 trial